Nkarta (NASDAQ:NKTX - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter.
Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.06. On average, analysts expect Nkarta to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Nkarta Price Performance
Shares of NASDAQ:NKTX traded down $0.12 during trading on Tuesday, hitting $1.87. 133,184 shares of the company's stock were exchanged, compared to its average volume of 1,080,673. The business's 50-day simple moving average is $1.76 and its 200 day simple moving average is $2.30. The company has a market cap of $132.34 million, a price-to-earnings ratio of -0.99 and a beta of 0.81. Nkarta has a 52-week low of $1.31 and a 52-week high of $8.23.
Analyst Ratings Changes
Several equities analysts have recently commented on NKTX shares. Stifel Nicolaus lowered their target price on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, March 27th. HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of Nkarta in a report on Thursday, March 27th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 target price on shares of Nkarta in a report on Wednesday, April 9th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Nkarta presently has an average rating of "Buy" and a consensus price target of $14.86.
Get Our Latest Stock Report on NKTX
About Nkarta
(
Get Free Report)
Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
Featured Stories
Before you consider Nkarta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.
While Nkarta currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
